Matches in SemOpenAlex for { <https://semopenalex.org/work/W69366164> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W69366164 endingPage "207" @default.
- W69366164 startingPage "199" @default.
- W69366164 abstract "To evaluate treatment of metastatic high-risk gestational trophoblastic neoplasia (GTN), including durable complete response rates to chemotherapy, factors affecting response to therapy, and overall survival.Forty women with metastatic high-risk GTN (International Federation of Gynecology and Obstetrics [FIGO] stages II-IV, score > or = 7) completed treatment between 1986 (when EMA-CO became the standard chemotherapy for high-risk disease) and 2009, including 26 who were treated primarily and 14 who were treated secondarily. Patients who had incomplete responses or developed resistance to EMA-CO or other methotrexate-containing regimens were treated with drug combinations employing etoposide and a platinum agent with or without bleomycin or ifosfamide. Adjuvant radiotherapy and surgery were used in selected patients. Clinical response and survival as well as factors affecting outcomes were analyzed retrospectively.The overall survival rate was 90% (36 of 40): 92% (24/26) for primary treatment and 86% (12/14) for secondary treatment. Twenty-one patients (53%) had durable complete clinical responses to initial treatment, 15 patients (37%) developed resistance to initial chemotherapy but were subsequently placed into lasting remission with platinum-based chemotherapy with or without surgery and 4 patients (10%) died of widespread metastatic disease. Durable complete clinical response to initial chemotherapy was significantly influenced by FIGO stage (II and III, 63%, vs. IV, 31%, p = 0.05) and risk factor score (< 12, 71%, vs. > or = 12, 32%, p < 0.02). Survival was also significantly associated with both FIGO stage (II and III, 100%, vs. IV, 69%, p < 0.01) and score (< 12, 100%, vs. > or = 12, 79%, p < 0.05).The use of EMA-CO chemotherapy as primary treatment and platinum-based chemotherapy along with surgical excision of resistant disease as secondary treatment for patients with metastatic high-risk GTN resulted in a survival rate of 90%. All patients who died had FIGO stage IV and risk factors scores > or = 12." @default.
- W69366164 created "2016-06-24" @default.
- W69366164 creator A5052993364 @default.
- W69366164 creator A5069375203 @default.
- W69366164 creator A5086072634 @default.
- W69366164 date "2010-07-16" @default.
- W69366164 modified "2023-09-27" @default.
- W69366164 title "Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score > or = 7." @default.
- W69366164 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20626175" @default.
- W69366164 hasPublicationYear "2010" @default.
- W69366164 type Work @default.
- W69366164 sameAs 69366164 @default.
- W69366164 citedByCount "11" @default.
- W69366164 countsByYear W693661642013 @default.
- W69366164 countsByYear W693661642014 @default.
- W69366164 countsByYear W693661642015 @default.
- W69366164 countsByYear W693661642016 @default.
- W69366164 countsByYear W693661642021 @default.
- W69366164 countsByYear W693661642022 @default.
- W69366164 countsByYear W693661642023 @default.
- W69366164 crossrefType "journal-article" @default.
- W69366164 hasAuthorship W69366164A5052993364 @default.
- W69366164 hasAuthorship W69366164A5069375203 @default.
- W69366164 hasAuthorship W69366164A5086072634 @default.
- W69366164 hasConcept C126322002 @default.
- W69366164 hasConcept C141071460 @default.
- W69366164 hasConcept C143998085 @default.
- W69366164 hasConcept C2776694085 @default.
- W69366164 hasConcept C2777506904 @default.
- W69366164 hasConcept C2778119113 @default.
- W69366164 hasConcept C2781059491 @default.
- W69366164 hasConcept C50440223 @default.
- W69366164 hasConcept C509974204 @default.
- W69366164 hasConcept C71924100 @default.
- W69366164 hasConceptScore W69366164C126322002 @default.
- W69366164 hasConceptScore W69366164C141071460 @default.
- W69366164 hasConceptScore W69366164C143998085 @default.
- W69366164 hasConceptScore W69366164C2776694085 @default.
- W69366164 hasConceptScore W69366164C2777506904 @default.
- W69366164 hasConceptScore W69366164C2778119113 @default.
- W69366164 hasConceptScore W69366164C2781059491 @default.
- W69366164 hasConceptScore W69366164C50440223 @default.
- W69366164 hasConceptScore W69366164C509974204 @default.
- W69366164 hasConceptScore W69366164C71924100 @default.
- W69366164 hasIssue "5-6" @default.
- W69366164 hasLocation W693661641 @default.
- W69366164 hasOpenAccess W69366164 @default.
- W69366164 hasPrimaryLocation W693661641 @default.
- W69366164 hasRelatedWork W1716315267 @default.
- W69366164 hasRelatedWork W1833898476 @default.
- W69366164 hasRelatedWork W1929177538 @default.
- W69366164 hasRelatedWork W1955563698 @default.
- W69366164 hasRelatedWork W1975227644 @default.
- W69366164 hasRelatedWork W1983758373 @default.
- W69366164 hasRelatedWork W2004681704 @default.
- W69366164 hasRelatedWork W2010443570 @default.
- W69366164 hasRelatedWork W2022350079 @default.
- W69366164 hasRelatedWork W2028063483 @default.
- W69366164 hasRelatedWork W2049523071 @default.
- W69366164 hasRelatedWork W2055635516 @default.
- W69366164 hasRelatedWork W2102748927 @default.
- W69366164 hasRelatedWork W2113955549 @default.
- W69366164 hasRelatedWork W2122185293 @default.
- W69366164 hasRelatedWork W2136501226 @default.
- W69366164 hasRelatedWork W2148665128 @default.
- W69366164 hasRelatedWork W2152552894 @default.
- W69366164 hasRelatedWork W2158806480 @default.
- W69366164 hasRelatedWork W2160168356 @default.
- W69366164 hasVolume "55" @default.
- W69366164 isParatext "false" @default.
- W69366164 isRetracted "false" @default.
- W69366164 magId "69366164" @default.
- W69366164 workType "article" @default.